INSIGHT 01Fact
93%
93% of applications are in Pharmaceuticals
556 applications in this field, 539 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsInnovative medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore medicines, formulations and related technologies through publications attributed to selected Hengrui Pharma legal entities.
≥618docs
52 per month · peak 2025-03 (82)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
93%
556 applications in this field, 539 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
598 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 30 | 37 | 76 | 49 | 56 | 47 | 51 | 41 | 47 | 46 | 48 | 44 |
| Organic fine chemistry | 14 | 19 | 44 | 28 | 32 | 26 | 33 | 18 | 23 | 22 | 25 | 23 |
| Biotechnology | 15 | 19 | 24 | 21 | 14 | 10 | 18 | 11 | 20 | 21 | 19 | 18 |
| Analysis of biological materials | 1 | 1 | 1 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 1 |
| Measurement | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Macromolecular chemistry, polymers | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Chemical engineering | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 2 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 21 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 1 of 1 entities
上交所披露中英文法人名;候选标准名的原始申请人示例对应同一法人。只纳入本体,联合申请中的其他法人不自动扩展到其独立文献。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250011411A1
The abstract combines an anti-SOST antibody with an antioxidant. Claim 1 further identifies the antibody through specified heavy- and light-chain CDR sequences and alternatives. The reading therefore concerns both antibody identity and formulation components, rather than every anti-SOST medicine.
US20250043022A1
The abstract describes a molecule binding both PSMA and CD3. Claim 1 requires at least one binding moiety for each target and specifies variable-region and CDR sequence alternatives. This supports a reading of dual-target molecular design; target names alone do not establish claim coverage or clinical performance.
22 publication offices · 618 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Other
Anti-sclerostin antibody, antigen binding fragment and medical use thereof
JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd
BiotechnologyPharmaceuticals
Invention publication
Kras g12d 억제제를 포함하는 약학적 조성물
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd
Pharmaceuticals
Other
A macrocyclic compound and use thereof
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / SHANGHAI SENHUI MEDICINE CO LTD
Pharmaceuticals
Other
Ctla4/tigit binding protein and the pharmaceutical use thereof
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD
BiotechnologyPharmaceuticals
Other
Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof
JIANGSU HENGRUI MEDICINE CO
Organic fine chemistryPharmaceuticals
Other
Anti-ilt4 antibody and pharmaceutical use thereof
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd
BiotechnologyPharmaceuticals
Other
Pharmaceutical composition comprising quinoline derivative or salt thereof
JIANGSU HENGRUI MEDICINE CO
Pharmaceuticals
Other
P-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor
JIANGSU HENGRUI MEDICINE CO
Organic fine chemistryPharmaceuticals
Other
Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
JIANGSU HENGRUI MEDICINE CO
Organic fine chemistryPharmaceuticals
Other
Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd
Organic fine chemistryPharmaceuticals
Invention publication
Anti-klb antibodies and uses
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd
BiotechnologyPharmaceuticals
Invention publication
Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd
Organic fine chemistryPharmaceuticals
Other
Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
Shanghai hengrui pharmaceutical co ltd / JIANGSU HENGRUI MEDICINE CO
Organic fine chemistryPharmaceuticals
Other
Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
JIANGSU HENGRUI MEDICINE CO
Pharmaceuticals
Other
Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
JIANGSU HENGRUI MEDICINE CO
Pharmaceuticals
Other
Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd
Organic fine chemistryPharmaceuticals
Invention publication
Anti-HER 2 antibody drug conjugate combined with anti-HER 2 antibody for treating tumors
JIANGSU HENGRUI MEDICINE CO
BiotechnologyPharmaceuticals
Invention publication
Method for screening and preparing immunomodulator
JIANGSU HENGRUI MEDICINE CO / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD
Analysis of biological materialsBiotechnology
Other
Pharmaceutical composition containing imidazoline derivative
JIANGSU HENGRUI MEDICINE CO
Pharmaceuticals
Other
Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
Shanghai hengrui pharmaceutical co ltd / JIANGSU HENGRUI MEDICINE CO
Organic fine chemistryPharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
江苏恒瑞医药股份有限公司
Configured aliases: Jiangsu Hengrui Pharmaceuticals Co., Ltd. · JIANGSU HENGRUI PHARMACEUTICALS CO LTD · JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD
Original review note: 上交所披露中英文法人名;候选标准名的原始申请人示例对应同一法人。只纳入本体,联合申请中的其他法人不自动扩展到其独立文献。
Review evidenceFound a wrong attribution or number? Tell us